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Background: Resistance rates to polymyxin B in surveillance studies have been very low despite its increasing use
worldwide as the last resort therapy for multidrug-resistant Gram-negative bacilli. However, two other resistance
phenotypes, hetero- and adaptive resistance, have been reported to polymyxin. We aimed to investigate the
presence of polymyxin B hetero- and adaptive resistance and evaluate its stability in carbapenem-resistant
Acinetobacter baumannii (CRAB) clinical isolates.
Methods: CRAB isolates were recovered from hospitalized patients at three Brazilian hospitals. Hetero-resistance
was determined by population analysis profile (PAP). Adaptive resistance was evaluated after serial daily passages of
isolates in Luria-Bertani broth containing increasing polymyxin B concentrations. MICs of polymyxin B of colonies
growing at the highest polymyxin B concentration were further determined after daily sub-cultured in antibiotic-free
medium and after storage at −80°C, in some selected isolates.
Results: Eighty OXA-23-producing CRAB isolates were typed resulting in 15 distinct clones. Twenty-nine randomly
selected isolates (at least one from each clone) were selected for hetero- resistance evaluation: 26 (90%) presented
growth of subpopulations with higher polymyxin B MIC than the original one in PAP. No isolate has grown at
polymyxin B concentrations higher than 2 mg/L. Polymyxin B MICs of subpopulations remained higher than the
original population after daily passages on antibiotic-free medium but returned to the same or similar levels after
storage. Twenty-two of the 29 isolates (at least one from each clone) were evaluated for adaptive resistance: 12 (55%)
presented growth in plates containing 64 mg/L of polymyxin B. Polymyxin B MICs decreased after daily passages on
antibiotic-free medium and returned to the same levels after storage.
Conclusions: The presence of subpopulations with higher polymyxin B MIC was extremely common and high-level
adaptive resistance was very frequent in CRAB isolates.
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The increasing worldwide prevalence of multi-drug
resistant, Acinetobacter baumannii, a major nosocomial
pathogen, particularly carbapenem-resistant strains, is of
great concern, since treatment becomes restricted to
very few options [1]. Polymyxins, both B and E (colistin),
are “old” polypeptide antibiotics that re-emerged in clinical
practice as the last resort therapy against multidrug-
resistant Gram-negative bacteria; many, including A.
baumannii, are only susceptible to these drugs [2].
Although resistance rates to polymyxins in surveillance
studies fortunately remain very low [3], two relatively poorly
understood resistance phenotypes, hetero- and adaptive
resistance, have been reported in these drugs [4,5].
The term hetero-resistance refers to a phenotype
characterized by the presence of different (drug-resistant
and –susceptible) populations in a single clinical specimen
or isolate [6], while adaptive resistance describes an
autoregulated phenomenon characterized by rapid
induction of resistance in the presence of drug and
reversal to the susceptible phenotype in its absence [7].
Hetero-resistance has been recently described for
colistin in some carbapenem-resistant A. baumannii,
Pseudomonas aeruginosa and Klebsiella pneumoniae
isolates [8-10], and other studies have demonstrated the
presence of adaptive resistance to polymyxins, mainly in
P. aeruginosa [7]. No study so far has neither investigated
the presence of hetero-resistance for polymyxin B, the
frequency of adaptive resistance in carbapenem-resistant
A. baumannii (CRAB) isolates, nor assessed the presence
of these distinct phenomena in the same isolates. The
aim of this study was to assess the occurrence of




CRAB isolates were selected from a total of 132
Acinetobacter spp. isolates (one isolate by patient)
consecutively recovered from patients admitted to three
tertiary-care hospitals from Porto Alegre, Brazil, from
March to December 2011. Isolates were identified by
Vitek 2 system. The following carbapenemase-encoding
genes were examined by multiplex PCR: blaOXA-23,
blaOXA-24, blaOXA-51, blaOXA-58 and blaOXA-143 genes [11].
A. baumannii species was confirmed by the presence of
the intrinsic blaOXA-51 gene [12].
MICs for polymyxin B, imipenem and meropenem were
determined by broth microdilution and interpreted
according to CLSI guidelines [13]. Pseudomonas aeruginosa
ATCC 27853 was included as quality control in all tests.
CRAB isolates were submitted to molecular typing
by ApaI DNA macrorestriction followed by PFGE
[14]. Results were interpreted using a dendrogramconstructed using the band-based Dice coefficient
method, and, for the purpose of this study, isolates
with >90% were considered a clone.
Hetero-resistance
Hetero-resistance in selected CRAB isolates was
determined by population analysis profile (PAP). Briefly,
solutions containing seven distinct bacterial inoculum,
ranging from 108 (0.5 McFarland standard) to 102 CFU/ml
were prepared to facilitate bacterial counting in each
plate. A 20 μL aliquot of each solution was spread on
Mueller-Hinton agar plates containing 0, 0.5, 1, 2, 3,
4 and 6 mg/L of polymyxin B. Colonies were counted
after 48 h of incubation at 35°C. The limit of counting was
20 CFU/ml. The frequency of hetero-resistant subpopula-
tions at the highest drug concentration was calculated
by dividing the number of colonies grown on antibiotic-
containing plates by the colony counts from the same
bacterial inoculum plated onto antibiotic-free plates [9].
MICs of polymyxin B of these subpopulations growing at
the highest polymyxin B concentration were determined
after daily sub-cultured in antibiotic-free medium for
4 days and after 75 days storage at −80°C, in some selected
isolates.
Adaptive resistance
Isolates were submitted to serial daily passages in freshly
prepared Luria-Bertani (LB) broth containing increasing
polymyxin B concentrations of 0.25 to 64 mg/L for a
total of nine days (adapted from Fernandez et al. [15].
MICs of polymyxin B of colonies growing at the highest
polymyxin B concentration were also determined after
daily subculture in antibiotic-free medium for 3 days
and after 60 days storage at −80°C, in some isolates.
Results
Of the 132 Acinetobacter spp., 124 were confirmed as A.
baumannii by the presence of blaOXA-51 gene, and 89
(71.7%) of these were CRAB isolates. All CRAB isolates
were positive for blaOXA-23 and no product of amplification
was detected for the other carbapenemase-encoding genes.
Of these, 80 were typed, resulting in 15 distinct clones.
MIC50 for both imipenem and meropenem were
64 mg/L and 32 mg/L and MIC90 were 128 mg/L
and 64 mg/L, respectively. MIC of polymyxin B
ranged from ≤0.125 mg/L to ≥64 mg/L. Twenty-nine
randomly selected isolates (at least one from each
clone) were selected for hetero-resistance evaluation.
PAP revealed the growth of subpopulation with 2- to
at least 4 fold dilutions higher polymyxin B MIC than
the original population in 26 (90%) of 29 isolates, including
at least one isolate representative of each clone (Table 1).
No isolate has grown at polymyxin B concentrations
higher than 2 mg/L. The proportions of higher MIC
Table 1 Results of population analysis profile (PAP) of selected carbapenem-resistant Acinetobacter baumannii isolates
Strain PFGE group MIC
(mg/L)
Highest concentration where growth




MIC after 4 days daily
passages in drug-free
medium (mg/L)
MIC after 75 days
storage (mg/L)
1 A ≤ 0.125 1 6.6 × 10-5 1 ≤ 0.125
2 A ≤ 0.125 2 6 × 10-5 2 ≤ 0.125
3 A 0.25 NG NA NA NA
4 A ≤ 0.125 1 1 × 10-7 1 NP
5 A 0.25 1 5 × 10-5 1 NP
6 A 0.25 1 1.5 × 10-6 1 NP
7 B ≤ 0.125 0.5 5 × 10-4 0.5 ≤ 0.125
8 B 0.25 1 2.5 × 10-7 1 0.25
9 B ≤ 0.125 0.5 1 × 10-6 0.5 NP
10 C ≤ 0.125 1 1.2 × 10-5 1 ≤ 0.125
11 C 1 1 NA 1 1
12 C ≤ 0.125 1 7.1 × 10-5 1 NP
13 D ≤ 0.125 1 1.3 × 10-6 1 NP
14 D ≤ 0.125 1 3.3 × 10-6 1 NP
15 E 0.25 1 1 × 10-6 1 NP
16 F 0.5 2 8.3 × 10-5 2 1
17 F ≤ 0.125 1 1 × 10-6 1 ≤ 0.125
18 G 0.25 1 7.5 × 10-5 1 0.25
19 H 0.25 1 3.3 × 10-4 1 0.25
20 I 0.25 2 3.3 × 10-5 2 1
21 I 0.5 1 3 × 10-6 1 1
22 J 0.25 1 1.4 × 10-4 1 0.25
23 K 0.25 NG NA NA NA
24 L ≤ 0.125 0.5 1.5 × 10-6 0.5 ≤ 0.125
25 L ≤ 0.125 1 4 × 10-4 1 NP
26 M ≤ 0.125 1 6.2 × 10-4 1 ≤ 0.125
27 N 0.5 2 6.6 × 10-5 2 1
28 N ≤ 0.125 0.5 1.5 × 10-5 0.5 NP
29 O ≤ 0.125 1 5 × 10-5 0.5 0.5
PAPs population analysis profiles, NA not applicable, NG no growth, NP not performed.
Barin et al. Annals of Clinical Microbiology and Antimicrobials 2013, 12:15 Page 3 of 5
http://www.ann-clinmicrob.com/content/12/1/15subpopulations ranged from 2.5 × 10-7 to 6.2 × 10-4. MICs
of polymyxin B of the 26 “higher MIC” subpopulations
remained higher than the original population MIC after
daily passages on polymyxin B-free medium (Table 1).
After storage, MIC for polymyxin B among 17 selected
subpopulations with higher MIC returned to levels similar
to the original population, with most presenting exactly
the same MIC of the original population.
Twenty-two of the 29 isolate (at least one from each
clone) were evaluated for adaptive resistance. In twelve
isolates, growth was observed in plates containing 64 mg/L
of polymyxin B (Table 2). After daily passages on polymyxin
B-free medium for 3 days the MIC of isolates growing at
64 mg/L remained the same for two isolates and decreased
1- to 2-fold dilutions for the other ten (Table 2). PolymyxinB MICs after 60 day storage (performed in four isolates)
were exactly the same of the MIC of baseline.
Discussion
Our study for the first time investigated the presence of
hetero- and adaptive resistance to polymyxin B in unrelated
OXA-23-producing CRAB isolates. Additionally, the
stability of these phenomena was evaluated in two
distinct conditions. Since the susceptibility breakpoint
for polymyxin B according to CLSI is 2 mg/L [13],
real hetero-resistance for polymyxin B was not found
in any isolate, differently from previous studies with
colistin [9,16,17]. However, the presence of “higher MIC”
subpopulations, within the susceptibility range, was
detected in 90% of tested isolates, including at least one








Highest concentration of polymyxin
B where growth was observed (mg/L)
MIC after 3 days daily passages
in drug-free medium (mg/L)
MIC after 60 days
storage (mg/L)
2 A ≤ 0.125 2 64 32 NP
3 A 0.25 NA 64 16 NP
5 A 0.25 1 NG NA NA
6 A 1 1 64 16 NP
7 B ≤ 0.125 0.5 64 16 NP
8 B 0.25 1 64 16 NP
9 B ≤ 0.125 0.5 64 16 NP
10 C ≤ 0.125 1 64 32 ≤ 0.125
12 C ≤ 0.125 1 64 16 NP
14 D ≤ 0.125 1 NG NA NA
15 E 0.25 1 NG NA NA
16 F 0.5 2 NG NA NA
17 F ≤ 0.125 1 NG NA NA
18 G 0.25 1 64 ≥ 64 NP
19 H 0.25 1 NG NA NA
20 I 0.25 2 NG NA NA
22 J 0.25 1 64 16 0.25
23 K 0.25 NA NG NA NA
24 L ≤ 0.125 0.5 64 16 ≤ 0.125
26 M ≤ 0.125 1 64 ≥ 64 ≤ 0.125
27 N 0.5 2 NG NA NA
29 O ≤ 0.125 1 NG NA NA
PAP population analysis profiles, NA not applicable, NG no growth, NP not performed.
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“higher MIC” subpopulations presented MICs 2- to at
least 4-fold dilutions higher than the original population.
The presence of adaptive resistance to polymyxin B
was shown in 55% of 22 tested isolates (present in 7 of
15 clones), all demonstrating high-level resistance to
polymyxin B (MIC = 64 mg/L). Although some mo-
lecular mechanisms of adaptive resistance to poly-
myxins, such as mutations in pmrCAB and lpxA gene
in A. baumannii [18,19] and PhoP-PhoQ, PmrA-PmrB
and recently ParR-ParS in P. aeruginosa [15], have
been characterized, the presence of this resistance
phenotype has not been systematically evaluated. Thus,
our study further suggests that adaptative resistance
might be most common than possibly expected, at
least in CRAB, since approximately half of tested
clones showed such adaptive phenotype. Indeed, the
frequency might be even higher if the agar plate with
the lowest polymyxin B concentration had <0.25 mg/L
of the drug. Although seven isolates with MIC ≤0.125
mg/L still have growth on these plates, these concen-
trations may have inhibited the growth of other eight
isolates.The present study also showed that the MIC of the
“higher MIC” subpopulations remained stable after 4-days
into antimicrobial-free medium, but returns to the MIC of
the original population after storage at −80°C, suggesting
that it might involve some molecular basis also associated
with an unstable phenotype. As expected, since without
the drug-sustaining effect the adaptive resistance is
unstable, the MICs of resistant isolates selected in the
adaptive resistance experiment decreased 1- to 2-fold
dilutions after serial passage into antimicrobial-free
medium and all tested isolates returns to the baseline
level after the storage at −80°C.
Only one isolate that has presented adaptive resistance
has not presented “higher MIC” subpopulation in PAP.
It belongs to the clone A, which has other three isolates
tested in both experiments, all showing the presence of
both phenomena. It is also interesting that these latter
three isolates were identical by typing while the former
showed 92% of similarity with these latter ones (data not
shown). Another isolate has neither presented “higher
MIC” subpopulation nor adaptive resistance and belongs
to a clone with two representative isolates among the 80
CRAB typed in this study.
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molecular determinants of these phenotypes in this
study. We also could not determine if the absence of real
hetero-resistance (i.e. presence of subpopulations with
MICs higher than the susceptibility breakpoint) was a
specific characteristic of polymyxin B, and would occur
with colistin, or “higher MIC” subpopulations within
the susceptibility range was only detected, instead of
subpopulations with “resistance MICs” because the
baseline MIC of half of the tested isolates were very
low (≤0.125 mg/L).
In summary, our study showed that the presence of
“higher MIC” subpopulations in CRAB isolates was
extremely common. Additionally, high-level adaptive
resistance was also very frequent. The clinical significance
of each phenomenon should be further investigated, since
both may potentially affect the outcomes of patients on
therapy with polymyxins.
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